GENE ONLINE|News &
Opinion
Blog

2021-01-20|

Lilly Strikes $1.6 Billion Deal with Merus for Cancer Treating Bispecific Antibodies

by Rajaneesh K. Gopinath
Share To

Loxo Oncology at Lilly is betting a whopping $1.6 billion on a research collaboration with Netherlands-based Merus for the development of cancer-treating drugs through the latter’s proprietary technology.

The exclusive license agreement intends to marry Loxo’s scientific and rational drug design expertise with Meru’s Biclonics® technology platform to yield three CD3-engaging T-cell re-directing bispecific antibody therapies, the companies announced on December 19th.

As per the terms, Merus will receive an upfront cash payment of $40 million and a $20 million worth equity investment made by Lilly on its common shares. Merus is also eligible to receive up to $540 million for each product on achieving certain development and commercialization milestones, as well as tiered royalties on the sales of products arising from the collaboration.

 

CD3-Engaging Bispecific Antibodies

Blinatumomab and Emicizumab are the two bispecific antibodies that are presently available for commercial use. Estimates suggest that the global market size of these therapeutics would reach $10 Billion By 2026.

Eli Lilly is not new to this class of drugs and has previously collaborated with Genmab for its DuoBody technology platform to develop bispecific antibodies. At present, several bispecific antibodies developed by big players such as Roche, Amgen, Pfizer, Sanofi among others are undergoing clinical trials for cancer treatment. Among them, the CD3-engaging bispecific antibodies are the most common.

By targeting the tumor-associated antigens on the cancer cells and CD3 on the surface of T-cells, the CD3-engaging bispecific antibodies activate T-cells to induce an immune response against cancer cells by bringing them together.

“CD3-engaging bispecific antibodies are rapidly becoming one of the most transformative immune-modulating modalities used to treat cancer. We expect these therapies will become an important component of the Loxo Oncology at Lilly biologics strategy,” said Jacob Van Naarden, Chief Operating Officer of Loxo Oncology at Lilly.

“Merus has built a differentiated platform and one that we believe can enable us to create bispecific antibody therapies with wider therapeutic indexes than those available today. We look forward to working closely with Merus to develop new potential medicines for patients with cancer,” he added.

 

Biclonics® Platform

Merus’ Biclonics® platform generates full-length IgG human bispecific antibodies that have a long half-life and low immunogenicity. Merus have struck profitable deals previously with Incyte and Ono Pharmaceutical to develop bispecific antibodies using this proprietary technology.

“The collaboration with Loxo Oncology at Lilly and their world class research capabilities opens up exciting possibilities for Merus’ Biclonics® platform,” said Bill Lundberg, MD., President and Chief Executive Officer at Merus.

“Our CD3 T-cell engager platform includes over 175 novel and diverse anti-CD3 common light chain antibodies across a wide range of affinities and attributes and enables functional screening of large libraries for optimal performance. We look forward to working together with Loxo Oncology at Lilly to define a new generation of medicines to treat cancer.”

Related Article: Roche Impresses with its Bispecific Antibody Portfolio for Blood Cancer Treatments

References
  1. https://investor.lilly.com/news-releases/news-release-details/lilly-and-merus-nv-announce-collaboration-discover-novel-t-cell

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Foreseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADC
2024-07-12
$115M Series A Boosts Myricx Bio’s ADC Development with Lilly and Novo Support
2024-07-11
LATEST
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
EVENT
Scroll to Top